Revitalizing Innovation

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC: Basic to Translational Science Pub Date : 2024-12-01 DOI:10.1016/j.jacbts.2024.08.006

Partha Sardar MD , Juan F. Granada MD , Louis A. Cannon MD

{"title":"Revitalizing Innovation","authors":"Partha Sardar MD , Juan F. Granada MD , Louis A. Cannon MD","doi":"10.1016/j.jacbts.2024.08.006","DOIUrl":null,"url":null,"abstract":"<div><div>Venture capital (VC) plays a critical role in driving advancements in medical device innovations through its investment in early-stage companies. However, a concerning trend has emerged over the past decade: a decline in interest from VC funds toward investing in medical devices. Particularly alarming is the more than 50% decrease in investment in early-stage medical device development over the span of 2 decades. In the last 2 years, there has been a significant drop in small to mid-cap VC funds allocated toward the cardiovascular (CV) device space. These obstacles are exacerbated by several factors, including high interest rates, inflation, global economic slowdown, and ongoing international conflicts. These declining investments stifle innovation and jeopardize the timely development of life-saving technologies, highlighting the urgent need for increased funding support. This manuscript delves into the pivotal role of VC in CV device innovation and examines the challenges and concerns stemming from the downturn in VC financing within the CV device sector.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 12","pages":"Pages 1435-1439"},"PeriodicalIF":8.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733749/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X24002985","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Venture capital (VC) plays a critical role in driving advancements in medical device innovations through its investment in early-stage companies. However, a concerning trend has emerged over the past decade: a decline in interest from VC funds toward investing in medical devices. Particularly alarming is the more than 50% decrease in investment in early-stage medical device development over the span of 2 decades. In the last 2 years, there has been a significant drop in small to mid-cap VC funds allocated toward the cardiovascular (CV) device space. These obstacles are exacerbated by several factors, including high interest rates, inflation, global economic slowdown, and ongoing international conflicts. These declining investments stifle innovation and jeopardize the timely development of life-saving technologies, highlighting the urgent need for increased funding support. This manuscript delves into the pivotal role of VC in CV device innovation and examines the challenges and concerns stemming from the downturn in VC financing within the CV device sector.

查看原文本刊更多论文

振兴创新：解决心血管设备风险投资低迷的影响。

风险投资（VC）通过对早期公司的投资，在推动医疗器械创新方面发挥着关键作用。然而，在过去十年中出现了一个令人担忧的趋势：风险投资基金对投资医疗设备的兴趣下降。尤其令人担忧的是，在20年的时间里，早期医疗设备开发的投资减少了50%以上。在过去两年中，分配给心血管（CV）设备领域的中小型风险投资基金大幅下降。高利率、通货膨胀、全球经济放缓和持续的国际冲突等因素加剧了这些障碍。这些减少的投资扼杀了创新，危及挽救生命的技术的及时开发，突出表明迫切需要增加资金支持。本文深入研究了VC在CV设备创新中的关键作用，并研究了CV设备领域内VC融资低迷所带来的挑战和担忧。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.